Relationship between transarterial chemoembolization treatment frequency and prognosis in hepatocellular carcinoma patients

Abstract

Transarterial chemoembolization (TACE) is an important treatment for intermediate-stage hepatocellular carcinoma (HCC) that often needs to be repeated. However, the optimal number of treatments remains unclear, and the relationship between repeated TACE and patient prognosis is complex and needs to be systematically investigated. Evidence shows that the initial efficacy of TACE is significant; however, with an increase in the number of treatments, the objective response rate of the tumor decreases, and TACE-related liver injury accumulates, which becomes a key factor restricting the long-term survival of patients with HCC. In recent years, the new paradigm of TACE combined with targeted therapy plus immunotherapy has shown significant advantages, improving the tumor remission rate, reducing the number of TACE required, and protecting liver function. In terms of prognosis prediction, the model is evolving from a static model based on baseline characteristics to a dynamic model that integrates treatment response. Frontier research has further explored prognostic prediction models based on genomics, radiomics, and machine learning, providing a direction for achieving higher accuracy of individualized prognostic prediction. This narrative review aims to synthesize the current evidence, explore the relationship between the number of TACE treatments and the prognosis of HCC patients, compare TACE alone versus TACE combined with systemic therapy, and review the methodological progress of prognosis-prediction models.

Keywords

Hepatocellular carcinoma / transarterial chemoembolization / therapeutic number / prognosis

References

[1] Bray F,Laversanne M,Sung H.et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2024 74 229 63

[2] Zheng RS,Chen R,Han BF.et al. [Cancer incidence and mortality in China, 2022] Zhonghua Zhong Liu Za Zhi 2024 46 221 31

[3] Rumgay H,Ferlay J,de Martel C.et al. Global, regional and national burden of primary liver cancer by subtype Eur J Cancer 2022 161 108 18

[4] Reig M,Forner A,Rimola J.et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update J Hepatol 2022 76 681 93 PMC8866082

[5] Lanza C,Ascenti V,Amato GV.et al. All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement J Clin Med 2025 14 314 PMC11766109

[6] Chen S,Peng Z,Zhang Y.et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat? Radiology 2021;298:680-92

[7] Sun X,Wei T,Kang T,Zhang Y,Huang G. Meta-analysis of the value of albumin-bilirubin grading on changes in liver function and its prognostic assessment in patients with hepatocellular carcinoma treated with transhepatic arterial chemoembolization World J Surg Oncol 2025 23 361 PMC12506359

[8] Zhou J,Sun H,Wang Z.et al. China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 Edition) Liver Cancer 2025 14 779 835 PMC12503762

[9] Vogel A,Chan SL,Dawson LA.et al. ; ESMO Guidelines Committee. Electronic address: [e-mail]. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Ann Oncol 2025 36 491 506

[10] Reig M,Sanduzzi-Zamparelli M,Forner A.et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update J Hepatol 2026 84 631 54

[11] Zhu H,Liu R,Jia Z.et al. Transarterial chemoembolization for hepatocellular carcinoma: Treatment algorithm proposed by Chinese College of Interventionalists (CCI) EngMedicine 2024 1 100037

[12] Zhong BY,Fan W,Guan JJ.et al. Combination locoregional and systemic therapies in hepatocellular carcinoma Lancet Gastroenterol Hepatol 2025 10 369 86

[13] Sangro B,Kudo M,Erinjeri JP.et al. ; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Lancet 2025 405 216 32 PMC12282661

[14] Kudo M,Ren Z,Guo Y.et al. ; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study Lancet 2025 405 203 15

[15] Zhu HD,Li HL,Huang MS.et al. ; CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) Signal Transduct Target Ther 2023 8 58 PMC9905571

[16] Jin ZC,Chen JJ,Zhu XL.et al. ; CHANCE2201 Investigators. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study EClinicalMedicine 2024 72 102622 PMC11090892

[17] Lo CM,Ngan H,Tso WK.et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 2002 35 1164 71

[18] Llovet JM,Real MI,Montaña X.et al. ; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 2002 359 1734 9

[19] China NHCotPsRo. Guideline for the diagnosis and treatment of primary liver cancer (2024 edition). J Multidiscip Cancer Manag 2024;10:17-68. (in Chinese) Available from https://www.nhc.gov.cn/yzygj/c100068/202404/b12cab9adae7424493cd2d387f018367.shtml [accessed 29 July 2026].

[20] Raoul JL,Gilabert M,Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective Liver Cancer 2014 3 119 24 PMC4057788

[21] Kudo M,Matsui O,Izumi N.et al. ; Liver Cancer Study Group of Japan. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update Oncology 2014 87 22 31

[22] Cheng AL,Amarapurkar D,Chao Y.et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel Liver Int 2014 34 174 83

[23] Zhong B,Zhang S,Zhu H,Wang W,Ni C. ; Clinical Guidelines Committee of Chinese College of Interventionalists. Transarterial chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement. Chin Med J 2024;137:2040-2 PMC11374215

[24] Yang C,Luo YG,Yang HC,Yao ZH,Li X. Effects of early TACE refractoriness on survival in patients with hepatocellular carcinoma: a real-world study J Hepatocell Carcinoma 2022 9 621 31 PMC9317376

[25] Li BR,Zhang LO. Research progresses in molecular mechanisms of TACE resistance of hepatocellular carcinoma Chin J Interv Imaging Ther 2025 22 425 8 (in Chinese)

[26] Zhang S,Wang WS,Zhong BY,Ni CF. Subsequent treatment after transarterial chemoembolization failure/refractoriness: a review based on published evidence J Clin Transl Hepatol 2022 10 740 7 PMC9396332

[27] Yu SCH,Chan L,Lee KF.et al. Ethiodized oil-based transarterial chemoembolization for hepatocellular carcinoma: randomized clinical trial of anhydrous cisplatin suspension versus cisplatin emulsion Radiology 2025 317 e242982

[28] Shang JN,Zhao ZW,Zheng X.et al. Clinical efficacy and safety of thermosensitive hydrogel in transcatheter arterial chemoembolization for the treatmentof primary liver cancer. J Med Imaging 2025;35:83-6. (in Chinese)

[29] Ogasawara S,Chiba T,Ooka Y.et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization Oncology 2014 87 330 41

[30] Arizumi T,Ueshima K,Minami T.et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma Liver Cancer 2015 4 253 62 PMC4698649

[31] Alharbi SR. Selective angiographic roadmap analysis (SARA) of hepatocellular carcinoma feeding arteries for transarterial chemoembolization Diagnostics 2025 15 2533 PMC12523393

[32] Clinical Guidelines Committee of Chinese College of Interventionalists. [Chinese clinical practice guidelines for transarterial interventions of hepatocellular carcinoma (2026 edition)] Zhonghua Yi Xue Za Zhi 2026 106 1998 2021

[33] Wang K,Feng J,Yu H.et al. Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial Signal Transduct Target Ther 2025 10 328 PMC12497873

[34] Peng Z,Fan W,Zhu B.et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH) J Clin Oncol 2023 41 117 27

[35] Li W,Lu M,Yuan G.et al. Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP Int J Surg 2025 111 7041 52 PMC12527776

[36] Zhang S,Zhong BY,Zhang L,Wang WS,Ni CF. Transarterial chemoembolization failure/refractoriness: a scientific concept or pseudo-proposition World J Gastrointest Surg 2022 14 528 37 PMC9258238

[37] Gao X,Sun Y,Huang J,Xu L,Huang H,Yang Z. Adrenomedullin orchestrates treatment resistance in hepatocellular carcinoma via immune microenvironment remodeling Front Genet 2025 16 1721263 PMC12736389

[38] Li J,Liu Y,Zheng R,Qu C,Li J. Molecular mechanisms of TACE refractoriness: directions for improvement of the TACE procedure Life Sci 2024 342 122540

[39] Liu CY,Wang MF,Xu XY.et al. Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization Ther Adv Med Oncol 2025 17 17588359251347363 PMC12214317

[40] Li R,Liu J,Ye F.et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC J Hepatol 2026 84 808 22

[41] Saito N,Tanaka T,Nishiohuku H.et al. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function Hepatol Res 2020 50 1176 85

[42] Hiraoka A,Kumada T,Kudo M.et al. ; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis Dig Dis 2017 35 602 10

[43] Chan SL,Sun HC,Xu Y.et al. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment Lancet 2025 406 731 78

[44] Lim RY,Koh B,Ng CH.et al. ; Liver Cancer Research Network. Hepatocellular carcinoma surveillance and survival in a contemporary Asia-Pacific cohort JAMA Netw Open 2025 8 e2520294 PMC12254890

[45] Kim BK,Shim JH,Kim SU.et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model Liver Int 2016 36 92 9

[46] Wang Q,Xia D,Bai W.et al. ; China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study J Hepatol 2019 70 893 903

[47] Xia D,Bai W,Wang Q.et al. ; China HCC-TACE study group. Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: an international observational study^☆ JHEP Rep 2025 7 101216 PMC11699734

[48] Han G,Berhane S,Toyoda H.et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach Hepatology 2020 72 198 212 PMC7496334

[49] Sieghart W,Hucke F,Pinter M.et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma Hepatology 2013 57 2261 73

[50] Hucke F,Sieghart W,Pinter M.et al. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE J Hepatol 2014 60 118 26

[51] Chen L,Ni CF,Chen SX.et al. A modified model for assessment for retreatment with transarterial chemoembolization in Chinese Hepatocellular Carcinoma Patients J Vasc Interv Radiol 2016 27 1288 97

[52] Hucke F,Pinter M,Graziadei I.et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma J Hepatol 2014 61 1287 96

[53] Adhoute X,Penaranda G,Naude S.et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process J Hepatol 2015 62 855 62

[54] Shen L,Zeng Q,Guo P.et al. Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data Nat Commun 2018 9 2230 PMC5993743

[55] Dang M,Wang S,Peng F.et al. Multiple features of cell-free mtDNA for predicting transarterial chemoembolization response in hepatocellular carcinoma Hepatol Commun 2025 9 e0652 PMC11868427

[56] Wei R,Liu Z,Ju L.et al. Using machine learning to predict advanced-stage progression of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization Radiol Imaging Cancer 2025 7 e250034 PMC12492425

[57] Song L,Zhu C,Shi Q.et al. Gelation embolism agents suppress clinical TACE-incited pro-metastatic microenvironment against hepatocellular carcinoma progression EBioMedicine 2024 109 105436 PMC11567102

[58] Gong F,Zheng L,Xu J.et al. Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: from animal models to a pilot clinical study Sci Adv 2025 11 eadv0885 PMC12219493

[59] Wu Z,Ouyang S,Gao J.et al. Role of radiomics-based multiomics panel in the microenvironment and prognosis of hepatocellular carcinoma Acad Radiol 2025 32 1961 70

[60] Wang G,Ding F,Chen K.et al. CT-based radiomics nomogram to predict proliferative hepatocellular carcinoma and explore the tumor microenvironment J Transl Med 2024 22 683 PMC11367757

[61] He X,Liu Y,Dai T.et al. Pathological study of the tumor microenvironment after neoadjuvant therapy in hepatocellular carcinoma: difference of TACE combined with antiangiogenics and immunotherapy Hepatol Commun 2025 9 e0787 PMC12401379